Vincere is developing small molecules to slow or halt Parkinson's disease. The distinct molecular targets and pathways are informed by a proprietary computational platform which integrates human genetics, genomics and other biomarker data to identify and rank-order pathogenic mechanisms which are validated in silico using simulated patient cells.